Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis

References

• MikolasevicILukendaVRackiSMilicSSladoje-MartinovicBOrlicLNonalcoholic fatty liver disease (NAFLD) – a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patientsClin Interv Aging201491295130325143715
   PubMed Web of Science ®Google Scholar
• KDOQIKDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney diseaseAm J Kidney Dis200749S12S15417276798
   PubMed Web of Science ®Google Scholar
• IshimuraEOkunoSKonoKGlycemic control and survival of diabetic hemodialysis patients – importance of lower hemoglobin A1c levelsDiabetes Res Clin Pract20098332032619135755
   PubMed Web of Science ®Google Scholar
• ShimaKKomatsuMKawaharaKMinaguchiJKawashimaSStringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysisNephrology20101563263820883284
   PubMed Web of Science ®Google Scholar
• NakamuraYHasegawaHTsujiMDiabetes therapies in hemodialysis patients: dipeptidase-4 inhibitorsWorld J Diabetes2015684084926131325
   PubMedGoogle Scholar
• VázquezESánchez-PeralesCGarcía-GarcíaFSudden death in incident dialysis patientsAm J Nephrol20143933133624751807
   PubMed Web of Science ®Google Scholar
• HarmankayaOAkalinNAkayHComparison of risk factors for cardiovascular disease in hemodialysis and peritoneal dialysis patientsClinics20157060160526375560
   PubMed Web of Science ®Google Scholar
• SchaferAIThe hypercoagulable statesAnn Intern Med19851028148283158262
   PubMed Web of Science ®Google Scholar
• FradeLJGde la CalleHAlavaINavarroJLCreightonLJGaffneyPJDiabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damageThromb Res1987475335403118498
   PubMed Web of Science ®Google Scholar
• SeshasalSRKaptogeSThompsonAEmerging Risk Factors CollaborationDiabetes mellitus, fasting glucose, and risk of cause-specific deathN Engl J Med201136482984121366474
   PubMed Web of Science ®Google Scholar
• ScheenAJCardiovascular effects of gliptinsNat Rev Cardiol201310738423296071
   PubMed Web of Science ®Google Scholar
• NomuraSOzakiYIkedaYFunction and role of microparticles in various clinical settingsThromb Res200812382318667228
   PubMed Web of Science ®Google Scholar
• NomuraSShimizuMClinical significance of procoagulant microparticlesJ Intensive Care2015721125705427
   PubMedGoogle Scholar
• NomuraSMicroparticle and atherothrombotic diseasesJ Atheroscler Thromb2016231926412494
   PubMed Web of Science ®Google Scholar
• MiyazakiYNomuraSMiyakeTHigh shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticlesBlood199688345634648896411
   PubMed Web of Science ®Google Scholar
• SinauridzeEIKireevDAPopenkoNYPlatelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated plateletsThromb Haemost20079742543417334510
   PubMed Web of Science ®Google Scholar
• CominaciniLPasiniAFGarbinUElevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic controlDiabetologia199538112211248591829
   PubMed Web of Science ®Google Scholar
• FestaAWilliamsKTracyRPWagenknechtLEHaffnerSMProgression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetesCirculation20061131753175916585388
   PubMed Web of Science ®Google Scholar
• LimYCSnappKKansasGSCamphausenRDingHLuscinskasFWImportant contributions of P-selectin glycoprotein ligand-1-mediated secondary capture to human monocyte adhesion to P-selectin, E-selectin, and TNF-α-activated endothelium under flow in vitroJ Immunol1998161250125089725249
   PubMed Web of Science ®Google Scholar
• NomuraSShouzuAOmotoSNishikawaMFukuharaSSignificance of chemokines and activated platelets in patients with diabetesClin Exp Immunol200012143744310971508
   PubMed Web of Science ®Google Scholar
• ShenGXVascular cell-derived fibrinolytic regulators and atherothrombotic vascular disordersInt J Mol Med199813994089852242
   PubMed Web of Science ®Google Scholar
• SobelBETaatjesDJSchneiderDJIntramural plasminogen activator inhibitor type-1 and coronary atherosclerosisArterioscler Thromb Vasc Biol2003231979198912920048
   PubMed Web of Science ®Google Scholar
• ZhaoRMaXXieXShenGXInvolvement of NADPH oxidase in oxidized LDL-induced upregulation of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cellsAm J Physiol Endocrinol Metab2009297E104E11119401454
   PubMed Web of Science ®Google Scholar
• NakagamiTHyperglycaemia and mortality from all cause and from cardiovascular disease in five populations of Asian originDiabetologia20044738539414985967
   PubMed Web of Science ®Google Scholar
• OuchiNKiharaSAritaYAdiponectin, an adipocyte- derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathwayCirculation20001021296130110982546
   PubMed Web of Science ®Google Scholar
• AritaYKiharaSOuchiNParadoxical decrease of an adipose-specific protein, adiponectin, in obesityBiochem Biophys Res Com1999257798310092513
   PubMed Web of Science ®Google Scholar
• HottaKFunahashiTAritaYPlasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetes patientsArterioscler Thromb Vasc Biol2000201595159910845877
   PubMed Web of Science ®Google Scholar
• WeyerCFunahashiTTanakaSHypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemiaJ Clin Endocrinol Metab2001861930193511344187
   PubMed Web of Science ®Google Scholar
• ChenHMontagnaniMFunahashiTShimomuraIQuonMJAdiponectin stimulates production of nitric oxide in vascular endothelial cellsJ Biol Chem2003278450214502612944390
   PubMed Web of Science ®Google Scholar
• HattoriYSuzukiMHattoriSKasaiKGlobular adiponectin upregulates nitric oxide production in vascular endothelial cellsDiabetologia2003461543154914551684
   PubMed Web of Science ®Google Scholar
• GodaMKadowakiTTeneligliptin for the treatment of type 2 diabetesDrugs Today20134961562924191255
   PubMed Web of Science ®Google Scholar
• KishimotoMTeneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesDiabetes Metab Syndr Obes2013618719523671395
   PubMedGoogle Scholar
• MorishitaRNakagamiHTeneligliptin: expectations for its pleiotropic actionExpert Opin Pharmacother20151641742625597385
   PubMed Web of Science ®Google Scholar
• NabenoMAkahoshiFKishidaHA comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active siteBiochem Biophys Res Commun201343419119623501107
   PubMed Web of Science ®Google Scholar
• KusunokiMSatoDNakamuraTDPP-4 inhibitor teneligliptin improves insulin resistance and serum lipid profile in Japanese patients with type 2 diabetesDrug Res201565532534
   PubMedGoogle Scholar
• ItoRFukuiTHayashiTTeneligliptin, a dipeptidyl peptidase-4 inhibitor, improves early-phase insulin secretion in drug-naïve patients with type 2 diabetesDrugs R D20151524525126224337
   PubMedGoogle Scholar
• TsuchimochiWUenoHYamashitaETeneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patientsEndocr J201562132025252844
   PubMed Web of Science ®Google Scholar
• OsumiKOzekiYSaitoSDevelopment and assessment of enzyme immunoassay for platelet-derived microparticlesThromb Haemost20018532633011246556
   PubMed Web of Science ®Google Scholar
• PolonskyKSGivenBDHirschLJAbnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitusN Engl J Med1988318123112393283554
   PubMed Web of Science ®Google Scholar
• Fukuda-TsuruSKakimotoTUtsumiHKiuchiSIshiiSThe novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in miceEur J Pharmacol201472320721524309217
   PubMed Web of Science ®Google Scholar
• NakagamiHPangZShimosatoTThe dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndromeHypertens Res20143762963524621463
   PubMed Web of Science ®Google Scholar
• HalabiAMaatoukHSieglerKEFaisstNLufftVKlauseNPharmacokinetics of teneligliptin in subjects with renal impairmentClin Pharm Drug Dev20132246254
   PubMed Web of Science ®Google Scholar
• MatsudaMShimomuraIIncreased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancerObes Res Clin Pract20137e330e34124455761
   PubMed Web of Science ®Google Scholar
• KimuraSInoguchiTYamasakiTA novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: in vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient ratsMetabolism20166513814526892525
   PubMed Web of Science ®Google Scholar
• OuchiNKiharaSAritaYNovel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein, adiponectinCirculation19991002473247610604883
   PubMed Web of Science ®Google Scholar
• ShimabukuroMHigaNAsahiTHypoadiponectinemia is closely linked to endothelial dysfunction in manJ Clin Endocrin Metab20038832363240
   PubMed Web of Science ®Google Scholar
• NomuraSShouzuAOmotoSCorrelation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitusThromb Res2008122394517920663
   PubMed Web of Science ®Google Scholar
• GuptaAKVermaAKKailashiyaJSinghSKKumarNSitagliptin: antiplatelet effect in diabetes and healthy volunteersPlatelets20122356557022950787
   PubMed Web of Science ®Google Scholar
• WangYLamKSChanLPost-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complexJ Biol Chem2006281163911640016621799
   PubMed Web of Science ®Google Scholar
• FülöpNMarchaseRBChathamJCRole of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular systemCardiovasc Res20077328829716970929
   PubMed Web of Science ®Google Scholar
• FülöpNMasonMMDuttaKImpact of type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heartAm J Physiol Cell Physiol2007292C1370C137817135297
   PubMed Web of Science ®Google Scholar
• OchiaiHOokaHShidaCIshikawaTInoueDOkazakiRAcarbose treatment increases serum total adiponectin levels in patients with type 2 diabetesEndocrin J200855549556
   PubMed Web of Science ®Google Scholar
• KnopFKVilsbøllTLarsenSMadsbadSHolstJJKrarupTNo hypoglycemia after subcutaneous administration of glucagons-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitisDiabet Care20032625812587
   PubMed Web of Science ®Google Scholar
• IshibashiYMatsuiTTakeuchiMYamagishiSSitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cellsHorm Metab Res20114373173421932180
   PubMed Web of Science ®Google Scholar
• PocaiACarringtonPEAdamsJRGlucagon-like peptide 1/glucagons receptor dual agonism reverses obesity in miceDiabetes2009582258226619602537
   PubMed Web of Science ®Google Scholar
• Kim Chung leTHosakaTYoshidaMExendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expressionBiochem Biophys Res Commun200939061361819850014
   PubMed Web of Science ®Google Scholar
• InabaMOkunoSKumedaYOsaka CKD Expert Research GroupGlycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injectionJ Am Soc Nephrol20071889690317267743
   PubMed Web of Science ®Google Scholar
• WadaNMoriKNakagawaCImproved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoringJ Diabetes Complications20152981310131326298521
   PubMed Web of Science ®Google Scholar
• FismanEZTenenbaumAAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesCardiovasc Diabetol20151412926415691
   PubMed Web of Science ®Google Scholar
• HashikataTYamaoka-TojoMKakizakiRTeneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetesHeart Vessels Epub2015813
   Web of Science ®Google Scholar